Home
/
Processa Pharmaceuticals, Inc.
/
Financials
/
Quarterly
Processa Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Processa Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2017
Sep 30, 2016
$5.0K
Nov 20, 2017
Q2
2017
Jun 30, 2016
$5.0K
Oct 4, 2017
Q1
2017
Mar 31, 2016
$5.0K
Oct 4, 2017
Q3
2016
Sep 30, 2015
$58.2K
Sep 8, 2017
Q2
2015
Jun 30, 2015
$20.0K
Aug 19, 2015
Q1
2016
Mar 31, 2015
$37.8K
Aug 7, 2017
Q3
2015
Sep 30, 2014
$52.6K
Dec 1, 2015
Q2
2015
Jun 30, 2014
$112.8K
Aug 19, 2015
Q1
2015
Mar 31, 2014
$20.4K
May 15, 2015
Q3
2014
Sep 30, 2013
$125.9K
Nov 13, 2014
Q2
2014
Jun 30, 2013
$97.3K
Aug 19, 2014
Q1
2014
Mar 31, 2013
$19.2K
May 14, 2014
Q3
2013
Sep 30, 2012
$49.1K
Nov 8, 2013
Q2
2013
Jun 30, 2012
$97.0K
Sep 6, 2013
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2023
Sep 30, 2023
$0
Nov 13, 2023
Q2
2023
Jun 30, 2023
$0
Aug 10, 2023
Q1
2023
Mar 31, 2023
$0
May 15, 2023
Q3
2022
Sep 30, 2022
$0
Nov 8, 2022
Q2
2022
Jun 30, 2022
$0
Aug 11, 2022
Q1
2022
Mar 31, 2022
$0
May 12, 2022
Q3
2021
Sep 30, 2021
$0
Nov 12, 2021
Q2
2021
Jun 30, 2021
$0
Aug 12, 2021
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2017
Sep 30, 2016
$5.0K
Nov 20, 2017
Q2
2017
Jun 30, 2016
$5.0K
Oct 4, 2017
Q1
2017
Mar 31, 2016
$5.0K
Oct 4, 2017
Q3
2016
Sep 30, 2015
$17.6K
Sep 8, 2017
Q2
2016
Jun 30, 2015
$32.8K
Aug 30, 2017
Q1
2016
Mar 31, 2015
$32.8K
Aug 7, 2017
Q3
2015
Sep 30, 2014
$16.6K
Dec 1, 2015
Q2
2015
Jun 30, 2014
$77.0K
Aug 19, 2015
Q1
2015
Mar 31, 2014
$7.4K
May 15, 2015
Q3
2014
Sep 30, 2013
$118.7K
Nov 13, 2014
Q2
2014
Jun 30, 2013
$96.0K
Aug 19, 2014
Q1
2014
Mar 31, 2013
$19.2K
May 14, 2014
Q3
2013
Sep 30, 2012
$48.6K
Nov 8, 2013
Q2
2013
Jun 30, 2012
$97.0K
Sep 6, 2013
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($3.44M)
Nov 6, 2025
Q3
2025
Jun 30, 2025
($3.93M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($3.93M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($2.83M)
May 8, 2025
Q2
2025
Mar 31, 2025
($2.83M)
Aug 7, 2025
Q3
2025
Mar 31, 2025
($2.83M)
Nov 6, 2025
Q3
2025
Sep 30, 2024
($3.38M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($3.01M)
Aug 7, 2025
Q3
2025
Jun 30, 2024
($3.01M)
Nov 6, 2025
Q2
2025
Mar 31, 2024
($2.73M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($2.73M)
May 8, 2025
Q3
2025
Mar 31, 2024
($2.73M)
Nov 6, 2025
Q3
2024
Sep 30, 2023
($2.08M)
Oct 30, 2024
Q3
2024
Jun 30, 2023
($2.61M)
Oct 30, 2024
Q2
2024
Jun 30, 2023
($2.61M)
Aug 13, 2024
Q3
2024
Mar 31, 2023
($4.02M)
Oct 30, 2024
Q2
2024
Mar 31, 2023
($4.02M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($4.02M)
May 10, 2024
Q3
2023
Sep 30, 2022
($6.02M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($5.16M)
Aug 10, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($3.49M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($3.95M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($2.85M)
May 8, 2025
Q3
2025
Sep 30, 2024
($3.42M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($3.08M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($2.81M)
May 8, 2025
Q3
2024
Sep 30, 2023
($2.17M)
Oct 30, 2024
Q2
2024
Jun 30, 2023
($2.71M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($4.11M)
May 10, 2024
Q3
2023
Sep 30, 2022
($6.06M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($5.17M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($3.23M)
May 15, 2023
Q3
2022
Sep 30, 2021
($3.11M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($3.46M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($2.19M)
May 12, 2022
Q3
2021
Sep 30, 2020
($2.96M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($802.0K)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($986.1K)
May 13, 2021
Q3
2020
Sep 30, 2019
($1.00M)
Nov 12, 2020
Q2
2020
Jun 30, 2019
($1.14M)
Aug 5, 2020